Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Low-Dose IL-2 Induces Regulatory T Cell–Mediated Control of Experimental Food Allergy

Benjamin Bonnet, James Vigneron, Béatrice Levacher, Thomas Vazquez, Fabien Pitoiset, Faustine Brimaud, Guillaume Churlaud, David Klatzmann and Bertrand Bellier
J Immunol June 1, 2016, 1501271; DOI: https://doi.org/10.4049/jimmunol.1501271
Benjamin Bonnet
*Sorbonne Universités, Université Pierre et Marie Curie, Université Paris 6, UMRS 959, I3, F-75013 Paris, France;
†INSERM, UMRS 959, I3, F-75013 Paris, France; and
‡Service de Biothérapies et Centre d'Investigation Clinique en Biothérapie, Groupe Hospitalier Pitié Salpêtrière, Assistance Publique - Hôpitaux de Paris, 75013 Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Benjamin Bonnet
James Vigneron
*Sorbonne Universités, Université Pierre et Marie Curie, Université Paris 6, UMRS 959, I3, F-75013 Paris, France;
†INSERM, UMRS 959, I3, F-75013 Paris, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for James Vigneron
Béatrice Levacher
*Sorbonne Universités, Université Pierre et Marie Curie, Université Paris 6, UMRS 959, I3, F-75013 Paris, France;
†INSERM, UMRS 959, I3, F-75013 Paris, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Béatrice Levacher
Thomas Vazquez
*Sorbonne Universités, Université Pierre et Marie Curie, Université Paris 6, UMRS 959, I3, F-75013 Paris, France;
†INSERM, UMRS 959, I3, F-75013 Paris, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Thomas Vazquez
Fabien Pitoiset
*Sorbonne Universités, Université Pierre et Marie Curie, Université Paris 6, UMRS 959, I3, F-75013 Paris, France;
†INSERM, UMRS 959, I3, F-75013 Paris, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fabien Pitoiset
Faustine Brimaud
*Sorbonne Universités, Université Pierre et Marie Curie, Université Paris 6, UMRS 959, I3, F-75013 Paris, France;
†INSERM, UMRS 959, I3, F-75013 Paris, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Faustine Brimaud
Guillaume Churlaud
*Sorbonne Universités, Université Pierre et Marie Curie, Université Paris 6, UMRS 959, I3, F-75013 Paris, France;
†INSERM, UMRS 959, I3, F-75013 Paris, France; and
‡Service de Biothérapies et Centre d'Investigation Clinique en Biothérapie, Groupe Hospitalier Pitié Salpêtrière, Assistance Publique - Hôpitaux de Paris, 75013 Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Guillaume Churlaud
David Klatzmann
*Sorbonne Universités, Université Pierre et Marie Curie, Université Paris 6, UMRS 959, I3, F-75013 Paris, France;
†INSERM, UMRS 959, I3, F-75013 Paris, France; and
‡Service de Biothérapies et Centre d'Investigation Clinique en Biothérapie, Groupe Hospitalier Pitié Salpêtrière, Assistance Publique - Hôpitaux de Paris, 75013 Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David Klatzmann
Bertrand Bellier
*Sorbonne Universités, Université Pierre et Marie Curie, Université Paris 6, UMRS 959, I3, F-75013 Paris, France;
†INSERM, UMRS 959, I3, F-75013 Paris, France; and
‡Service de Biothérapies et Centre d'Investigation Clinique en Biothérapie, Groupe Hospitalier Pitié Salpêtrière, Assistance Publique - Hôpitaux de Paris, 75013 Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bertrand Bellier
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF + SI
  • PDF
Loading

Abstract

Regulatory T cells (Tregs) are pivotal for maintenance of immune self-tolerance and also regulate immune responses to exogenous Ags, including allergens. Both decreased Treg number and function have been reported in allergic patients, offering new therapeutic perspectives. We previously demonstrated that Tregs can be selectively expanded and activated by low doses of IL-2 (ld-IL-2) inducing immunoregulation without immunosuppression and established its protective effect in autoimmune diseases. In this study, we evaluated the ability of ld-IL-2 to control allergy in an experimental model of food allergy. Ld-IL-2 induced Treg expansion and activation that elicited protection against clinical manifestations of food allergy in two mouse models with OVA and peanut. This clinical effect was lost in Treg-depleted mice, demonstrating the major contribution of Tregs in ld-IL-2 efficacy. Mechanistic studies further indicated that protection from allergy could be explained by a Treg-dependent local modification of the Th1/Th2 balance and an inhibition of mast cell recruitment and activation. Preventive and therapeutic effects of ld-IL-2 were observed over a 7-mo-period, highlighting its long-term efficacy. This study demonstrated that ld-IL-2 is efficient to prevent and to treat allergic immune responses, and thus represents a promising therapeutic strategy for managing allergic diseases.

Footnotes

  • This work was supported by Université Pierre et Marie Curie, INSERM, and the French state funds managed by the Agence Nationale de la Recherche within the Programme d’ Investissements d’Avenir under reference ANR-11-IDEX-0004-02.

  • The online version of this article contains supplemental material.

  • Received June 4, 2015.
  • Accepted April 29, 2016.
  • Copyright © 2016 by The American Association of Immunologists, Inc.
Next
Back to top

In this issue

The Journal of Immunology: 209 (1)
The Journal of Immunology
Vol. 209, Issue 1
1 Jul 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Low-Dose IL-2 Induces Regulatory T Cell–Mediated Control of Experimental Food Allergy
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Low-Dose IL-2 Induces Regulatory T Cell–Mediated Control of Experimental Food Allergy
Benjamin Bonnet, James Vigneron, Béatrice Levacher, Thomas Vazquez, Fabien Pitoiset, Faustine Brimaud, Guillaume Churlaud, David Klatzmann, Bertrand Bellier
The Journal of Immunology June 1, 2016, 1501271; DOI: 10.4049/jimmunol.1501271

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Low-Dose IL-2 Induces Regulatory T Cell–Mediated Control of Experimental Food Allergy
Benjamin Bonnet, James Vigneron, Béatrice Levacher, Thomas Vazquez, Fabien Pitoiset, Faustine Brimaud, Guillaume Churlaud, David Klatzmann, Bertrand Bellier
The Journal of Immunology June 1, 2016, 1501271; DOI: 10.4049/jimmunol.1501271
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Improved Durability to SARS-CoV-2 Vaccine Immunity following Coimmunization with Molecular Adjuvant Adenosine Deaminase-1
  • Viral Delivery of IL-7 Is a Potent Immunotherapy Stimulating Innate and Adaptive Immunity and Confers Survival in Sepsis Models
  • SM03, an Anti-CD22 Antibody, Converts Cis-to-Trans Ligand Binding of CD22 against α2,6-Linked Sialic Acid Glycans and Immunomodulates Systemic Autoimmune Diseases
Show more IMMUNOTHERAPY AND VACCINES

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606